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Abstract
Background  The contraceptive efﬁ  cacy and 
tolerability of a new ﬂ  exible extended regimen of 
ethinylestradiol (EE) 20 μg/drospirenone (DRSP) 
3 mg to extend the menstrual cycle and enable 
management of intracyclic (breakthrough) bleeding 
(ﬂ  exibleMIB) was investigated and the bleeding 
pattern compared with a conventional 28-day 
regimen and a ﬁ  xed extended 124-day regimen.
Study design  This Phase III, 2-year, multicentre, 
open-label study randomly (4:1:1) allocated women 
(aged 18–35 years) to the following regimens: 
ﬂ  exibleMIB (24–120 days’ active hormonal intake 
with 4-day tablet-free intervals); conventional 
(24 days’ active hormonal intake followed by a 
4-day hormone-free interval); or ﬁ  xed extended 
(120 days’ uninterrupted active hormonal intake 
followed by a 4-day tablet-free interval). Primary 
outcomes included the number of bleeding/
spotting days during Year 1 (all regimens) and the 
number of observed unintended pregnancies over 
2 years (ﬂ  exibleMIB only).
Results  Results were analysed in 1067 women 
(full analysis set). The mean number of bleeding/
spotting days was lower with the ﬂ  exibleMIB vs 
the conventional regimen [41.0±29.1 (95% CI 
38.8–43.3) vs 65.8±27.0 (95% CI 62.2–69.4) days, 
p<0.0001; treatment difference −24.8 (95% CI 
−29.2 to −20.3) days]. The corresponding value 
for the ﬁ  xed extended regimen was 60.9±51.1 
(95% CI 53.9–67.9) days. The Pearl Index for the 
ﬂ  exibleMIB regimen was 0.64 (95% CI 0.28–1.26). 
All regimens had comparable tolerability proﬁ  les.
Conclusions  EE 20 μg/DRSP 3 mg administered as 
a ﬂ  exible extended regimen with MIB is effective, 
well tolerated and is associated with statistically 
signiﬁ  cantly fewer bleeding/spotting days and 
fewer withdrawal bleeding episodes vs EE/DRSP 
in a conventional 28-day regimen. The ﬂ  exibleMIB 
also provided statistically signiﬁ  cantly fewer 
spotting days vs EE/DRSP in a ﬁ  xed extended 124-
day regimen (post hoc evaluation). The ﬂ  exibleMIB 
regimen allows women to extend their menstrual 
cycle and manage their intracyclic (breakthrough) 
bleeding.
Introduction
Many modern-day combined oral con-
traceptives (COCs) have a 28-day cycle, 
usually comprising 21 days of active (i.e. 
hormonal) tablets followed by a 7-day 
hormone-free interval. Newer COCs with 
a shortened hormone-free interval (i.e. 24 
days of active hormonal intake followed 
by a 4-day hormone-free interval), which 
are associated with more sustained ovar-
ian suppression and reduced hormonal 
fluctuations,1 are available; such COCs still, 
however, follow the 28-day cycle paradigm. 
The 28-day cycle was originally designed to 
allow for monthly bleeding, even though 
this was not necessary, primarily to mimic 
the natural menstrual cycle and to reassure 
women that they were not pregnant.2
The long-term availability of COCs 
with a hormone-free interval has led 
many women to mistakenly believe that 
it is natural to have a withdrawal bleed 
during COC use or that missing a with-
drawal bleed is associated with nega-
tive health effects.3–7 Despite this, given 
the choice, a substantial proportion of 
women would welcome a reduction in 
the frequency of their menstrual bleed-
ing. Survey data indicate that as many as 
59% of women aged 15–49 years would 
be interested in not menstruating every 
month.7 8 Furthermore, up to 46% of such 
women would rather not have a period at 
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Key message points
▶   A ﬂ  exible extended regimen of ethinylestradiol (EE) 20 μg/
drospirenone (DRSP) 3 mg is an effective and well-tolerated 
combined oral contraceptive.
▶   A ﬂ  exible extended regimen of EE/DRSP is associated with 
fewer bleeding/spotting days than a conventional 28-day 
regimen and a ﬁ  xed extended 124-day regimen of EE/DRSP.
▶   The ﬂ  exible extended regimen of EE/DRSP allows women 
to extend their menstrual cycle and manage any intracyclic 
(breakthrough) bleeding that may occur during the ﬂ  exible 
intake phase.
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all.7 8 Reasons for wanting to reduce menstrual bleed-
ing include reducing monthly menstrual-related com-
plaints, better hygiene and improved quality of life.5 7
At present, women who are prepared to use COCs and 
want to reduce the frequency of their menstrual bleeding 
have two options. First, they can opt to (either occasion-
ally or regularly) skip the hormone-free interval of their 
cyclical COC, thus extending the length of time that they 
take active treatment;2 although continually postponing 
the use of conventional regimen COCs is not a labelled 
indication. Second, they can opt to use COCs in fixed 
extended regimens of up to 1 year;9–12 however, these 
preparations are currently only available in the USA. 
Fixed extended regimens have been shown to be effec-
tive with safety profiles that are similar to conventional 
COCs;5 9 10 12–14 however, they are often associated with 
an increased risk of breakthrough bleeding versus cycli-
cal COCs.12 14 Many women are not willing to tolerate 
such bleeding, and in some studies overall dropout rates 
of greater than 50% have been observed.5 9 10 12 14
Ethinylestradiol (EE) 20 µg/drospirenone (DRSP) 3 
mg in a 24/4 regimen is an effective and well-  tolerated 
COC.15–17 It was hypothesised that a regimen that 
extended beyond the conventional 28 days and gave 
women the flexibility to manage their intracyclic 
(breakthrough) bleeding (MIB) would be appealing. 
The objective of the current study was to investigate the 
efficacy and tolerability of EE 20 µg/DRSP 3 mg admin-
istered in a flexible extended regimen (‘flexibleMIB’) that 
allowed women to extend the menstrual cycle as well 
as manage their intracyclic bleeding in comparison to 
a conventional 28-day regimen. A fixed extended 124-
day regimen was also included to assess the safety over a 
continuous 120-day intake period, the maximum dura-
tion possible with the flexibleMIB regimen.
Methods
Study design
This was a Phase III, multicentre, randomised, open-
label, parallel-group study conducted at 37 centres 
in Germany, Canada and The Netherlands between 
December 2005 (first subject, first visit) and October 
2008 (last subject, last visit). The study (proto-
col number, 308683; ClinicalTrials.gov identifier, 
NCT00266032) was conducted in accordance with 
the Declaration of Helsinki and the International 
Conference on Harmonisation–Good Clinical Practice 
guidelines. All participants received adequate informa-
tion about the study and signed an informed consent 
form before entering the study.
The study consisted of two phases: a 1-year com-
parative phase where women were randomly allo-
cated to receive EE 20 µg/DRSP 3 mg administered as 
a   flexibleMIB, conventional 28-day or fixed extended 
regimen and a 1-year safety extension phase during 
which the majority of women received the flexibleMIB 
regimen. For the most part, data from the 1-year com-
parative phase are reported here, while data from the 
safety extension phase are reported elsewhere.18
Study population
Healthy females aged between 18 and 35 years who 
requested contraceptive protection were eligible to 
participate in the study. Women were required to 
be in good general health with a normal cervical 
smear test result at or in the 6-month period prior to 
screening, and smokers could participate so long as 
they were 30 years of age or younger at the time of 
screening. The main exclusion criteria included: use 
of other contraceptive methods, sterilisation, preg-
nancy or lactating, body mass index <18 and >30 
Table 1 Deﬁ  nitions of withdrawal bleeding, intracyclic bleeding and scheduled and unscheduled bleeding in women 
who received ethinylestradiol 20 μg/drospirenone 3 mg administered as a ﬂ  exibleMIB, ﬁ  xed extended or conventional 
28-day regimen
Term FlexibleMIB Fixed extended  Conventional 28-day
Withdrawal bleeding Started before or at the latest on the fourth day of the subsequent cycle 
AND ended at the earliest 4 days before the ﬁ  rst day of the tablet-free 
interval of the current cycle or later
Started on or after Day 21 of the cycle and lasted until 
at least Day 25 of the same cycle OR started on or 
after Day 25 of the cycle, but before Day 25 of the next 
cycle
If more than one episode satisﬁ  ed both of the above criteria, the ﬁ  rst 
episode to occur was considered to be the withdrawal bleeding episode 
of that cycle
If more than one episode satisﬁ  ed either of the above 
criteria, the ﬁ  rst episode to occur was considered to be 
the withdrawal bleeding episode of that cycle
Intracyclic bleeding Bleeding episodes (either spotting or 
bleeding) shorter than 3 days
All other (unexpected) bleeding episodes All other (unexpected) bleeding episodes
Scheduled bleeding Any bleeding days that occurred during the tablet-free interval 
or up to 4 days after the tablet-free interval
Not evaluated*
Unscheduled bleeding Any bleeding days that occurred while taking active treatment, 
unless they occurred (i) up to 4 days after the tablet-free interval 
or (ii) during Days 1–7 of the ﬁ  rst treatment cycle
Not evaluated*
*As tablet-free intervals were not documented with the conventional 28-day regimen, an analysis of scheduled and unscheduled bleeding was only 
conducted for the two extended regimens.
MIB, management of intracyclic (breakthrough) bleeding.
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kg/m2, presence or history of any vascular diseases 
or coagulation disorders, known hypersensitivity 
to any of the study drug ingredients, and any dis-
ease or condition that could interfere with the study 
medication.
Study regimens
Flexible extended regimen with management of intracyclic 
(breakthrough) bleeding
With the flexibleMIB regimen, women received EE/
DRSP for a flexible number of cycles (minimum three, 
maximum 13 in 1 year), each of which was separated 
by a 4-day tablet-free interval. With this regimen, tablet 
taking was continuous for at least 24 days (‘mandatory 
phase’); in this manner, the minimum cycle length was 
28 days and the design of the COC was based on the 
approved and marketed conventional 24/4-day regi-
men of EE 20 µg/DRSP 3 mg (YAZ®; Bayer HealthCare 
Pharmaceuticals). After the mandatory phase, the cycle 
could continue up to a maximum of 120 consecutive 
days (i.e. for a maximum cycle length of 124 days). A 
4-day tablet-free interval had to be taken at the latest 
after 120 days of continuous tablet intake. Between 
Days 25 and 120 (‘flexible phase’) women were 
instructed to observe a 4-day tablet-free interval if they 
experienced three consecutive days of bleeding and/or 
spotting. After each 4-day tablet-free interval, women 
started a new cycle with a minimum of 24 days and a 
maximum of 120 days of tablet intake.
Conventional 28-day regimen
With the conventional 28-day regimen, women 
received EE/DRSP for 13 cycles. Each cycle comprised 
24 days of active hormonal intake followed by a 4-day 
interval in which women took hormone-free (placebo) 
tablets to induce withdrawal bleeding.
Fixed extended regimen
With the fixed extended regimen, women received EE/
DRSP for three cycles. Each cycle comprised 120 days 
of uninterrupted active hormonal intake followed by a 
4-day tablet-free interval.
Study medication was to be commenced on the first 
day of menstrual bleeding (new COC starters) or sched-
uled withdrawal bleeding (COC switchers) following 
the baseline visit. During active hormonal intake, tab-
lets could be taken in the morning or the evening, but 
the interval between two tablets had to remain as close 
as possible to 24 hours. If a woman missed a tablet she 
was to take it as soon as possible (even if this meant 
taking two tablets at the same time); thereafter, tablet 
intake was to continue as normal. With regard to the 
rules for the use of back-up contraception, a missed 
tablet was defined as tablet intake that was delayed by 
more than 24 hours.
Study outcomes
Primary outcomes
The main primary outcome was the total number of 
bleeding/spotting days during the 1-year comparative 
Figure 1  Disposition of women in the 1-year comparative phase of the study. FAS, full analysis set (deﬁ  ned as subjects who received 
at least one dose of study medication and had at least one clinical observation after administration of study medication). MIB, 
management of intracyclic (breakthrough) bleeding.
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phase. The total number of bleeding/spotting days per 
subject was calculated by summing all of the days with 
a bleeding intensity of spotting or greater.
The other primary outcome was the number of 
observed unintended pregnancies with the flexibleMIB 
regimen over the 2 years of treatment. (This variable 
was originally a secondary outcome, but was changed 
to a co-primary outcome based on a recommendation 
by the Food and Drug Administration during a scien-
tific advisory meeting.) The number of observed unin-
tended pregnancies was used to measure contraceptive 
efficacy, calculated using the Pearl Index (number of 
pregnancies divided by the exposure in woman-years 
multiplied by 100) and by life-table analysis. The Pearl 
Index was only calculated in women who received the 
flexibleMIB regimen as the number of women in the 
other two groups were planned for a comparison of 
bleeding pattern and safety and were, therefore, not 
powered for a reliable calculation of the pregnancy 
rate. A life-table analysis was performed for the time to 
the occurrence of a pregnancy. The cumulative failure 
rate (i.e. the probability of getting pregnant) was cal-
culated using the Kaplan–Meier estimator on the basis 
of pregnancies that were considered to have occurred 
after up to 2 years of treatment.
Secondary outcomes
Secondary outcomes included bleeding pattern and 
cycle control outcomes over the first year. Bleeding 
pattern parameters included the number and length 
of bleeding/spotting episodes and spotting-only epi-
sodes (days with bleeding/spotting or spotting only 
preceded and followed by at least two bleed-free 
days); these parameters were determined for each sub-
ject for 90-day reference periods. The first reference 
period started on the first day of study medication 
intake. Cycle control parameters included withdrawal 
bleeding, intracyclic bleeding, scheduled bleeding and 
unscheduled bleeding defined according to the differ-
ent regimens (Table 1). Cycle control parameters were 
determined for each subject at every cycle.
Bleeding data were recorded by every subject using 
diary cards that were to be completed on a daily basis. 
Each day, subjects rated their bleeding as none, spotting, 
light, normal or heavy. Diary records were to start with 
the onset of the first menstrual or withdrawal bleeding 
episode following the baseline visit (i.e. the bleeding epi-
sode that prompted the initiation of study medication), 
and were to continue until the end of the last bleeding 
episode within the study. The daily diary cards were also 
used to monitor compliance with study medication.
A self-reported, non-validated, menstrual bleeding 
questionnaire was used to assess the impact of the 
three regimens on subjects’ menstrual bleeding and the 
problems associated with it; data were collected retro-
spectively for the 12 weeks prior to inclusion into the 
study and at four time points during the study. Subjects 
in each of the three groups also completed the 22-item 
validated Psychological General Well-Being Index 
(PGWBI) at baseline and at two time points during the 
study. A third questionnaire was used to assess satisfac-
tion with the regimen in women who received the two 
extended regimens; this was completed at the end of 
the first year of the study.
Safety outcomes
The following safety outcomes were evaluated: adverse 
events (AEs); laboratory variables; bone markers and 
bone mineral density; general physical and gynaeco-
logical findings (including the outcomes of cervical 
smear tests); endometrial biopsies; and vital signs and 
body weight. AEs for the first year of the study are 
reported here; data pertaining to long-term safety out-
comes are reported separately.18
Table 2  Demographic and baseline characteristics of women who received ethinylestradiol 20 μg/drospirenone 3 mg 
administered as a ﬂ  exibleMIB, conventional 28-day or ﬁ  xed extended regimen (full analysis set)
Characteristic
FlexibleMIB 
(n=642)
Conventional 28-day 
(n=216)
Fixed extended 
(n=209)
Age  (years) 24.8  (4.4)  24.3 (4.3)  24.8 (4.5)
Height  (cm) 167.2 (6.3) 167.8 (5.8) 168.0  (6.2)
BMI (kg/m2)  22.5 (2.7)  22.6 (2.8)  22.5 (2.6)
Caucasian ethnicity [n  (%)] 636 (99.1) 212 (98.1) 202  (96.7)
Current smokers [n  (%)] 205 (31.9)  67 (31.0)  67  (32.1)
Contraceptive method at screening [n (%)]
 COCs 538 (83.8) 158 (73.1) 148  (70.8)
 Condoms  77 (12.0)  48 (22.2)  52  (24.9)
 None  17  (2.6)   7  (3.2)   5  (2.4)
    Other  10  (1.6)   3  (1.4)   4  (1.9)
Data are presented as mean (SD) unless otherwise stated.
The full analysis set was deﬁ  ned as all women who received at least one dose of study medication and had at least one clinical observation after 
administration of study medication.
BMI, body mass index; MIB, management of intracyclic (breakthrough) bleeding; COCs, combined oral contraceptives.
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Statistical analysis
Descriptive statistics [number, mean, standard devia-
tion (SD)] were calculated for each quantitative vari-
able, while frequencies were given for categorical 
data. Regarding the primary outcome of the number 
of bleeding/spotting days, the main evaluation was a 
comparison of the flexibleMIB regimen versus the con-
ventional regimen using Student’s t-test assuming a 
normal distribution. A statistical comparison between 
the flexibleMIB and the fixed extended regimen was not 
planned, although a post hoc analysis was conducted.
For the 1-year comparative phase, subjects were 
randomly allocated in a 4:1:1 ratio to the flexibleMIB, 
conventional and fixed extended regimens. The ran-
domisation sequence was generated by the responsible 
biometrician and performed by the central randomisa-
tion group at Bayer HealthCare Pharmaceuticals using 
the software package SAS (Release 9.1 or higher; SAS 
Institute, Cary, NC, USA). Randomisation blocks of 12 
were used. Eligible subjects were assigned their ran-
domisation numbers via an interactive voice response 
system to avoid any assignment bias in this open-label 
study. With this system, neither the subject nor the 
investigator knew the identity of the study regimen 
before the assignment of the randomisation number.
Analysis set
The full analysis set (FAS) was defined as all women 
who received at least one dose of study medication 
and for whom at least one clinical observation follow-
ing administration of study medication was available. 
The evaluation of the primary outcomes was based on 
the FAS, as was the evaluation of safety data. It should 
be noted that 67 subjects were excluded from the FAS 
because of invalid data owing to suspected misconduct 
at one study centre.
Sample size
In order to undertake a reasonable assessment of safety, 
it was considered that a treatment duration equivalent 
to 10 000 cycles of 28 days should be achieved for the 
flexibleMIB regimen. Based on previous experience with 
cycle control studies using conventional regimens, it 
Figure 2  Mean number of bleeding/spotting days in the 
comparative phase with ethinylestradiol 20 μg/drospirenone 
3 mg administered as a ﬂ  exibleMIB, conventional 28-day or ﬁ  xed 
extended regimen (full analysis set). Data are presented as 
mean (95% CI). The full analysis set was deﬁ  ned as all subjects 
who received at least one dose of study medication and had 
at least one clinical observation after administration of study 
medication. *p<0.0001 vs ﬂ  exibleMIB (post hoc analysis for the 
ﬁ  xed extended regimen comparison). MIB, management of 
intracyclic (breakthrough) bleeding. 
Figure 3  Analysis of bleeding/spotting days in the comparative phase with ethinylestradiol 20 μg/drospirenone 3 mg administered 
as (a) ﬂ  exibleMIB, (b) conventional 28-day and (c) ﬁ  xed extended regimens (full analysis set). The full analysis set was deﬁ  ned as all 
subjects who received at least one dose of study medication and had at least one clinical observation after administration of study 
medication. MIB, management of intracyclic (breakthrough) bleeding.
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was considered that at least 200 subjects per treatment 
arm would be sufficient to reliably describe the bleed-
ing data.
Given that the flexibleMIB is the preferred regimen 
and assuming a difference of 10 days and a SD of 28 
days plus an annual dropout rate of 40%, approxi-
mately 660 subjects were needed for the flexibleMIB 
regimen, and 225 subjects were needed for each of the 
other two regimens. This resulted in a proposed total 
sample size of 1110 subjects, which would result in 
a power of at least 94% to show superiority of the 
  flexibleMIB regimen over the conventional regimen in 
terms of the primary bleeding variable.
The proposed sample size for the flexibleMIB group 
was also expected to provide sufficient statistical power 
to reliably determine contraceptive efficacy, as per the 
guidelines of the European Medicines Agency.
Results
Overall, 1312 women were screened, and 1166 of these 
were subsequently randomised to one of the three reg-
imens. Reasons for non-randomisation are shown in 
Figure 1. Study medication was administered to 1134 
subjects in the three groups. After excluding the 67 
subjects from a study centre with suspected study mis-
conduct, 1067 women took at least one dose of study 
medication and had at least one clinical observation 
after administration of study medication; these women 
comprised the FAS (flexibleMIB, n=642; conventional, 
n=216; fixed extended, n=209; Figure 1). The demo-
graphic and baseline characteristics of women included 
in the FAS were generally similar in the three groups 
(Table 2). Study medication was completed by 88.5% 
of all subjects in the FAS. Overall, 83.9%, 80.3% and 
72.9% of all women randomised to the flexibleMIB, con-
ventional and fixed extended regimens, respectively, 
completed treatment. The mean treatment exposure 
times were 339 days for the flexibleMIB regimen, 340 
days for the conventional regimen and 318 days for 
the fixed extended regimen.
Primary outcomes
The mean number of bleeding/spotting days within 
the comparative phase was significantly lower with 
the flexibleMIB regimen than with the conventional 
regimen [41.0±29.1 (95% CI 38.8–43.3; n=640) 
vs 65.8±27.0 (95% CI 62.2–69.4; n=215) days, 
p<0.0001; treatment difference −24.8 (95% CI 
−29.2 to −20.3) days; Figure 2). The mean number 
of bleeding/spotting days with the fixed extended 
regimen was 60.9±51.1 (95% CI 53.9–67.9) days 
(n=209). No statistical testing was preplanned for 
this comparison; however, the between-treatment dif-
ference was in the same order of magnitude as that 
Table 3  Bleeding pattern outcomes by 90-day reference period in women who 
received ethinylestradiol 20 μg/drospirenone 3 mg administered as a ﬂ  exibleMIB, 
conventional 28-day or ﬁ  xed extended regimen (full analysis set)
Reference period FlexibleMIB Conventional 28-day  Fixed extended
Bleeding/spotting days
  1 13.7  (n=605) 22.6 (n =203) 21.7 (n =182)
 2 10.7  (n =575) 15.3 (n =198) 16.0 (n =174)
 3  9.4  (n =554) 14.8 (n =189) 14.1 (n =161)
 4  8.2  (n =522) 14.2 (n =171)   9.4 (n =146)
Spotting-only days
 1  6.5  8.0 12.7
 2  5.4  5.0  9.8
 3  4.7  4.9  9.0
 4  4.3  4.7  6.8
Bleeding-only days
 1  7.2 14.6  9.0
 2  5.3 10.2  6.3
 3  4.6  9.8  5.1
 4  3.9  9.5  2.6
All data refer to mean values.
The full analysis set was deﬁ  ned as all subjects who received at least one dose of study medication and had at least 
one clinical observation after administration of study medication.
Subject numbers shown for bleeding/spotting days apply to the data for spotting-only days and bleeding-only days.
Reference periods 1, 2, 3 and 4 refer to Days 1–90, 91–180, 181–270 and 271–360, respectively.
NB. The greatest number of bleeding/spotting days, spotting-only days and bleeding-only days was reported in the 
ﬁ  rst reference period, which was not unexpected. For all three groups, subjects initiated intake of study medication 
on the ﬁ  rst day of menstrual or withdrawal bleeding after baseline. Therefore, the ﬁ  rst reference period contained 
additional bleeding days (associated with the menstrual cycle prior to the start of study medication) compared with the 
subsequent reference periods.
MIB, management of intracyclic (breakthrough) bleeding.
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between the flexibleMIB regimen and the conventional 
regimen, and a post hoc analysis indicated that the 
flexibleMIB regimen significantly reduced the mean 
number of bleeding/spotting days versus the fixed 
extended regimen (p<0.0001). The variation in the 
overall number of days of bleeding in the first year 
in women who received the flexibleMIB regimen was 
similar to that in women who received the conven-
tional regimen (Figure 3). The fixed extended regi-
men showed more variability (Figure 3).
Over the full 2 years of the study, the Pearl Index for 
the flexibleMIB regimen was 0.64 (95% CI 0.28–1.26) 
based on eight pregnancies and 1253 woman-years of 
exposure. One of these pregnancies was deemed to 
be a subject failure; the others were reported with-
out information supporting subject failure, and were 
therefore classified as method failures. The cumulative 
pregnancy rate for up to 2 years of treatment (deter-
mined using the Kaplan–Meier life-table analysis) was 
1.28% (95% CI 0.62–2.66). This corresponds to 99% 
contraceptive protection.
Secondary outcomes
Bleeding pattern
The flexibleMIB regimen was associated with the low-
est mean number of bleeding/spotting days (analysed 
by 90-day reference periods). The mean number of 
bleeding/spotting days was generally higher with the 
conventional regimen at all time points (Table 3). 
During the 1-year comparative phase, the proportion 
of bleeding/spotting days was lowest in women treated 
with the flexibleMIB regimen (13.3±11.1%); corre-
sponding proportions in recipients of the conventional 
and fixed extended regimens were 20.4±9.8% and 
23.1±20.7%, respectively.
Cycle control
The mean number of cycles in women who received the 
flexibleMIB, conventional and fixed extended regimens 
Figure 4  Analysis of cycle length with ethinylestradiol 20 μg/drospirenone 3 mg administered as a ﬂ  exibleMIB regimen (full analysis 
set). The full analysis set was deﬁ  ned as all subjects who received at least one dose of study medication and had at least one clinical 
observation after administration of study medication. MIB, management of intracyclic (breakthrough) bleeding.
Table 4  Characteristics of intracyclic bleeding in women who received ethinylestradiol 20 μg/drospirenone 3 mg 
administered as a ﬂ  exibleMIB, conventional 28-day or ﬁ  xed extended regimen (full analysis set)
Characteristic
FlexibleMIB 
(n=622)
Conventional 28-day 
(n=213)
Fixed extended 
(n=190)
Number of intracyclic bleeding days
  Bleeding/spotting 6.6 (8.7) 6.7 (13.5) 29.7 (32.9)
  Bleeding only 2.2 (4.5) 3.7   (8.5) 18.9 (29.2)
Number of intracyclic bleeding/spotting episodes 2.8 (3.4) 1.7   (2.8)   4.2   (3.8)
Maximum length of intracyclic bleeding/spotting episodes 4.1 (4.0) 5.8   (4.9) 16.5 (14.8)
Maximum intensity* of intracyclic bleeding 2.7 (0.9) 3.0   (0.9)   3.2   (1.0)
Data are presented as mean (SD).
*Intensity scores: 1, none; 2, spotting; 3, light; 4, normal; 5, heavy.
The full analysis set was deﬁ  ned as all subjects who received at least one dose of study medication and had at least one clinical observation after 
administration of study medication.
MIB, management of intracyclic (breakthrough) bleeding.
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was 4.5±2.1 (median 4.0), 11.9±2.9 (median 13.0) 
and 2.8±0.9 (median 3.0), respectively. Values for mean 
cycle length were 78.2±39.8 (median 72.0), 27.9±1.8 
(median 28.0) and 121.6±27.9 (median 124.0) days, 
respectively. The cycle length observed with the 
  flexibleMIB regimen is shown in Figure 4. In women who 
received the flexibleMIB regimen, approximately 20% of 
all cycles were of the maximum length of 124 days.
Withdrawal bleeding episodes occurred approximately 
every 8–10 weeks in recipients of the flexibleMIB regimen 
and, as expected, every 4 weeks in recipients of the con-
ventional regimen and every 124 days in recipients of the 
fixed extended regimen. The mean length of withdrawal 
bleeding episodes appeared to be shorter with the con-
ventional 28-day regimen (4.4–5.2 days) than with the 
flexibleMIB regimen (7.5–14.2 days) and fixed extended 
regimen (2.0–10.5 days). For the majority of withdrawal 
bleeding episodes, the maximum intensity was reported 
as light to normal with all three regimens.
The mean number of intracyclic bleeding/spotting 
days during the comparative phase appeared similar in 
recipients of the flexibleMIB and conventional regimens, 
and lower than that in recipients of the fixed extended 
regimen (Table 4). A similar result was observed for 
the number of days with intracyclic bleeding only, and 
the mean number and maximum length of intracyclic 
bleeding episodes (Table 4). The maximum intensity of 
intracyclic bleeding was deemed spotting or bleeding 
with light intensity with all three regimens (Table 4).
The flexibleMIB regimen appeared to have a higher 
mean number of scheduled bleeding days (23.3±14.3 
days) than the fixed extended regimen (14.0±5.9 days). 
In contrast, the opposite was observed for the number 
of unscheduled bleeding days, which was lower with 
the flexibleMIB regimen than with the fixed extended 
regimen (17.1±17.4 vs 46.6±48.4 days).
Subject questionnaires
Improvements in various items of the menstrual bleed-
ing questionnaire were observed, compared with the 
12 weeks prior to inclusion into the study. Between-
treatment differences in symptoms were found, prima-
rily as a result of extended cycles resulting in an absence 
of menstrual bleeding-related events. Aspects related 
to the PGWBI, user satisfaction and menstruation-re-
lated symptoms with the three regimens is shown in 
Table 5. Of those women who had painful menstrua-
tion before the start of the study, 52.5% treated with 
the flexibleMIB regimen and 58.1% treated with the 
fixed extended regimen reported feeling better having 
received treatment. In addition, 86.0% and 79.1% of 
women, respectively, would recommend their regimen 
to a friend.
Safety
The occurrence of AEs during the comparative phase is 
reported in Table 6. The vast majority (93.1%) of AEs that 
occurred were mild or moderate in intensity; there was no 
difference in AE intensity between the three groups.
There were four serious AEs (SAEs) that were consid-
ered to be possibly related to study medication: focal 
nodular hyperplasia of the liver, uterine leiomyoma 
and two cases of deep vein thrombosis (DVT). More 
detailed data pertaining to long-term safety outcomes 
during the 2-year study are reported separately.18
Table 5  User satisfaction, Psychological General Well-Being Index score and menstruation-related symptoms in 
women who received ethinylestradiol 20 μg/drospirenone 3 mg administered as a ﬂ  exibleMIB, conventional 28-day or 
ﬁ  xed extended regimen (full analysis set)
Parameter FlexibleMIB (n=179) Conventional 28-day (n=18) Fixed extended (n=43)
Regimen satisfaction* [n (%)]
  Very satisﬁ  ed 111 (62.0) – 25 (58.1)
  Quite satisﬁ  ed   60 (33.5) – 14 (32.6)
Improved frequency of painful 
menstruations* [n (%)]
138 (77.1) 14 (77.8) 35 (81.4)
Improved intensity of painful 
menstruations* [n (%)]
133 (74.3) 16 (88.9) 38 (88.4)
PGWBI (change in total score 
from baseline to Week 51)
+0.35 −1.02 +0.26
Menstruation-related symptoms [n (%)] Baseline 
(n=642)
Week 51 
(n=554)
Baseline
(n=216)
Week 51 
(n=196)
Baseline
(n=209)
Week 51 
(n=165)
  Mild abdominal/pelvic pain 296 (46.1) 132 (23.8) 90 (41.7) 54 (29.0) 84 (40.2) 25 (15.2)
  Mild backache 158 (24.6)   94 (17.0) 57 (26.4) 30 (16.1) 57 (27.3) 19 (11.5)
  Daily activities slightly impaired   38   (5.9)   12   (2.2)   8   (3.7) 11   (5.9)   7   (3.3)   0      (0)
  Conﬁ  ned to bed for part of a single day   14   (2.2)     7   (1.3)   3   (1.4)   0      (0) 10   (4.8)   1   (0.6)
  Leisure activities slightly affected  72  (11.2)   19   (3.5) 18   (8.3)   9   (4.8) 19 (13.9)   6   (3.7)
*Assessed in women who reported painful menstruation before the start of study medication (32.3% of women who received the ﬂ  exibleMIB regimen, 14.4% 
of women who received the conventional regimen and 26.1% of women who received the ﬁ  xed extended regimen).
MIB, management of intracyclic (breakthrough) bleeding; PGWBI, Psychological General Well-Being Index.
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Discussion
The results of this trial show that EE 20 µg/DRSP 3 
mg administered in a flexibleMIB regimen was associ-
ated with significantly fewer bleeding/spotting days 
over a period of 1 year compared with the conven-
tional regimen. It was also associated with a simi-
larly significant reduction in the number of days of 
bleeding/spotting than the fixed extended regimen. 
In addition, the   flexibleMIB regimen showed good 
contraceptive efficacy similar to other COCs and was 
well tolerated.
The flexibleMIB regimen had a more favourable effect 
on various aspects of menstrual bleeding than the two 
other regimens, including fewer bleeding/spotting days 
overall and fewer days with unscheduled bleeding. The 
reduction in bleeding/spotting days with the flexibleMIB 
regimen compared with the conventional regimen was 
mainly related to 50% fewer days of menstruation-like 
bleeding. The reduction in bleeding/spotting days with 
the flexibleMIB regimen compared with fixed extended 
regimen could be related to one-half the number of days 
with spotting only (Figure 2). Overall, the flexibleMIB 
regimen was associated with a reduced proportion of 
bleeding days of any intensity; by one-third compared 
with the conventional regimen and potentially by one-
third compared with the fixed extended regimen. In 
addition, the flexibleMIB regimen appeared to be associ-
ated with less variation in the overall number of days 
of bleeding/spotting than the fixed extended regimen. 
On average, women taking the flexibleMIB regimen can 
expect to have approximately 40 days of bleeding per 
year in comparison to approximately 65 days with 
the conventional regimen (corresponding to 5 days of 
bleeding per cycle).
The mean number of intracyclic bleeding/spotting 
days in recipients of the flexibleMIB regimen seemed to 
be markedly lower than that in recipients of the fixed 
extended regimen. This may be because women who 
received the latter regimen were instructed to take 
120 days of uninterrupted active hormonal intake irre-
spective of any bleeding/spotting. In contrast, women 
who received the flexibleMIB regimen who experienced 
three consecutive days of bleeding/spotting during 
Days 25–120 were instructed to observe a 4-day tablet-
free interval; in this manner, the 3 days of bleeding/
spotting that preceded the tablet-free interval became 
part of the bleeding episode of the withdrawal bleed. 
As such, the length of the whole bleeding episode in the 
flexibleMIB group was prolonged by 3 days because of 
the stipulated ‘wait and see’ period of three consecutive 
days of bleeding/spotting. Ultimately, this may translate 
into fewer bleeding days overall and better cycle con-
trol with fewer episodes of intracyclic bleeding, which 
could improve the acceptability of the flexibleMIB regi-
men compared with the fixed extended regimen.
The acceptability of the flexibleMIB regimen may also 
be influenced by the fact that the onset of bleeding 
could be managed, within the limitations of the regi-
men. With the flexibleMIB regimen women could take 
treatment for 24 days, 120 days, or for an amount 
of time between 25 and 120 days, depending on the 
occurrence of bleeding/spotting. Although this study 
did not allow the flexibleMIB regimen group to observe 
a 4-day tablet-free interval at any time between Days 
Table 6  Adverse events occurring in the comparative phase of the study with ethinylestradiol 20 μg/drospirenone 
3 mg administered as a ﬂ  exibleMIB, conventional 28-day or ﬁ  xed extended regimen (full analysis set)
Adverse event FlexibleMIB (n=642) Conventional 28-day (n=216) Fixed extended (n=209)
At least one AE [n (%)] 415 (64.6) 150 (69.4) 150  (71.8)
Treatment withdrawn due to AE [n  (%)]  57 (4.0)  14  (2.5)  29  (4.8)
AE* [n (%)]
 Nasopharyngitis 105  (16.4)  45 (20.8)  37 (17.7)
 Headache  82  (12.8)  37 (17.1)  37 (17.7)
 Diarrhoea  43 (6.7)  16  (7.4)  18  (8.6)
 Cystitis  21 (3.3)   8  (3.7)  17  (8.1)
 Dysmenorrhoea  29 (4.5)  14  (6.5)   9  (4.3)
 Vomiting  28 (4.4)   7  (3.2)  11  (5.3)
TAEs [n  (%)] 133  (20.7)  56 (25.9)  71 (34.0)
TAEs occurring in >3% [n (%)]
 Headache  33 (5.1)  19  (8.8)  18  (8.6)
 Breast  pain  20 (3.1)   7  (3.2)   7  (3.3)
 Dysmenorrhoea   8 (1.2)   9  (4.2)   4  (1.9)
 Lower  abdominal  pain   7 (1.1)   4  (1.9)   9  (4.3)
 Vaginal  haemorrhage   2 (0.3)   0  (0)   8  (3.8)
*AEs (listed in order of overall frequency) are those that occurred in >5% of women in any of the three groups.
The full analysis set was deﬁ  ned as all subjects who received at least one dose of study medication and had at least one clinical observation after 
administration of study medication.
AE, adverse event; MIB, management of intracyclic (breakthrough) bleeding; TAE, treatment-related adverse event.
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25 and 120 (i.e. independent of the occurrence of 
bleeding/spotting), in clinical practice women may do 
so. In fact, in the flexibleMIB group 5.9% of all cycles 
ended with a 4-day break during the flexible intake 
phase without the preceding days of intracyclic (break-
through) bleeding. The importance to women of being 
able to manage their withdrawal bleeding should 
not be underestimated. Many women find menstrual 
bleeding both painful and inconvenient,7 with 75.6%, 
28.8% and 48.4% of women reporting that their men-
strual bleeding interfered with their sex lives, work 
lives or sporting activities, respectively.19 The free-
dom to decide when their menstrual bleeding occurs 
also appears to be important to women; data indicate 
that women using COCs will deviate from the recom-
mended intake pattern in order to prevent bleeding 
during special occasions or holidays/weekends.3 In the 
current study, approximately 20% of all cycles were 
of the maximum length of 124 days, indicating that 
around 80% of the intake cycles required flexibility 
in length in order to manage three consecutive days of 
bleeding/spotting.
In this study, the tolerability of the three regimens 
was comparable based on an assessment of AEs occur-
ring during the first year of use and similar to those 
reported for other low-dose COCs, including EE 
20 µg/DRSP 3 mg in a 24/4 regimen.15–17 20–22 It should 
be noted that the type of AE reporting did not allow 
for an assessment of the frequency of AEs in an indi-
vidual woman. A similar AE rate between the three 
groups, therefore, does not necessarily mean a similar 
frequency in individual women. As such, the expecta-
tion that menstrual-related complaints will occur less 
frequently when a woman has less frequent menstrual 
periods is not disproved by this finding. Four SAEs 
that were considered to be possibly related to study 
medication were recorded: focal nodular hyperpla-
sia, uterine leiomyoma and two cases of DVT. A more 
comprehensive overview of the safety and tolerability 
of the three regimens investigated in the current study 
is reported elsewhere.18
Comparison of the bleeding profile of the flexible 
extended regimen in this study with fixed extended 
COC regimens is difficult, primarily because of the way 
in which treatment was administered and data were 
collected. Specifically, beyond the first 24 days of man-
datory intake, cycle length with the flexible extended 
regimen was variable because women had to take a 
4-day tablet-free interval between Days 25 and 120 if 
they experienced three consecutive days of bleeding/
spotting; in contrast, in studies of fixed extended regi-
mens, cycle length was fixed. Some previous studies 
have, however, reported the overall number of bleed-
ing/spotting days. In a 1-year study, women were ran-
domised to receive EE 30 µg/levonorgestrel (LNG) 
150 µg in a 91-day extended regimen for four cycles 
(n=456) or EE 30 µg/LNG 150 µg in a 21/7 regimen 
for 13 cycles (n=226).12 There was a reduced number of 
bleeding/spotting days in women who received the fixed 
extended regimen (median 35 days) versus the conven-
tional 28-day regimen (median 53 days), similar to the 
findings reported here. The proportion of women on 
the EE/LNG fixed extended regimen who prematurely 
discontinued medication because of any AE or bleed-
ing irregularities was 14.9% and 7.7%, respectively. In 
the current study these values were lower: 6.4% and 
1.2% with the flexibleMIB regimen, respectively. In a 
second study, women received EE 20 µg/LNG 100 µg 
(n=16) administered for 168 days without a pill-free 
interval or as six 28-day cycles (n=16) on an open-la-
bel basis.13 Over the course of the study, women on the 
fixed extended regimen had a mean of 25.9±29.2 days 
of bleeding/spotting. In a similarly designed, double-
blind study, in which 31 women received EE 20 µg/
norethindrone acetate 1 mg for 168 days, 31.5±21.8 
days of vaginal bleeding were reported.14 It should be 
noted that the latter two studies were conducted over 
168 days, whereas bleeding outcomes in the current 
study are reported for a full year.
Conclusions
The results of this study show that EE/DRSP adminis-
tered as a flexibleMIB regimen is associated with fewer 
days of bleeding/spotting and fewer withdrawal bleed-
ing episodes over 1 year compared with the same hor-
monal combination in a conventional 28-day regimen. 
It also appeared to provide fewer spotting days com-
pared with the same combination in a fixed extended 
124-day regimen. The flexibleMIB regimen provides 
reliable contraceptive efficacy, and has a compara-
ble tolerability profile to the conventional and fixed 
extended regimens. The flexibleMIB regimen is unique 
in that it extends the menstrual cycle and provides 
women with the flexibility to manage their intracyclic 
(breakthrough) bleeding.
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